SkyePharma PLC : Board Change

SKYEPHARMA PLC - BOARD CHANGE - SENIOR INDEPENDENT NON-EXECUTIVE DIRECTOR

LONDON, UK, 28 February 2014 - Skyepharma PLC (LSE SKP),the expert oral and inhalation drug delivery company, regrets to announce that its Senior Independent Non-Executive Director, Alan Bray, has passed away following a sudden and unexpectedly severe recurrence of a previous illness.

Alan joined the Board of Skyepharma in September 2004 and chaired the Audit Committee since December 2004.

A search for a replacement Non-Executive Director and Chairman of the Audit Committee had been initiated some time ago, as Alan was approaching nine years' service on the Board.  This search process has been accelerated.

Frank Condella, Chairman of the Board of Skyepharma, commented:

"We are all shocked and saddened that Alan Bray has passed away so suddenly and our sympathies go out to his wife Marion and family.  Alan was a very diligent, reliable and conscientious Board member and he played a key role in steering the Company to the strengthened position it is in today.  He will be deeply missed by his fellow Board members and everyone at Skyepharma." 

Editors' Note

Alan Bray (aged 69) was appointed to the Board as a Non-Executive Director in September 2004. He became Senior Independent Director in June 2006 and was Chairman of the Audit Committee until his death. He was also a member of the Nomination & Governance and Remuneration Committees.

Previously, Alan Bray was a Senior Partner at Deloitte LLP in the financial services practice. He worked with retail and investment banks, insurance companies and asset management firms and was seconded for a time to the Department of Trade and Industry. He was responsible for Deloitte LLP's risk management policies and procedures in its financial services practice and was a serving member on a DTI Supervisory Board and Audit Committee.

-Ends-

For further information please contact:

About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products.  The Group is eligible for revenues from 15 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses.  The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies.  For more information, visitwww.skyepharma.com